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Summary Seventeen patients with Hodgkin's disease (HD) were treated with high-dose chemotherapy
followed by autologous bone marrow transplantation (ABMT). Eleven patients were resistant to initial
therapy. Three patients had relapsed and were still responders to second or third line therapy. Three patients
had relapsed but were progressing under second or third line therapy. Pre-ABMT chemotherapy included
high dose cyclophosphamide in all patients (50 mgKg- I day- 1 bolus for 4 days), most often associated with
BCNU or CCNU, aracytine and 6 thioguanine. Four patients received additional TBI (10 Gy). In 9 patients
complete remission (CR) was achieved, 4 failed to respond and 4 cases were not evaluable due to early death.
Among CR patients, 2 died from late toxicity, 4 relapsed between the 2nd and 5th months, but 3 patients
remain in CR, off therapy at 25+, 43+, and 66+ months, including 1/11 initially resistant and 2/6 who had
relapsed. There were 9 treatment related deaths: 6 due to infection, cardiac failure and 2 multiorgan failure.
The high complete response rate in these heavily pretreated patients suggests that there may be an
indication for high dose therapy earlier in resistant HD. Moreover under such conditions, treatment related
morbidity would be expected to be lower.
Hodgkin's disease (HD) is one of the most therapy-
sensitive malignant lymphomas and in several long
term studies more than 80% of the patients have
been considered cured following radiotherapy,
chemotherapy or usually a combination of both.
Nevertheless, irrespective of age, initial presenta-
tion, stage or histologic subgroup, a few patients
remain resistant to treatment. These can present,
either with initial resistance, an incomplete response
to chemotherapy, or early and often multiple,
relapses (Teillet-Thiebaud et al., 1984). For this
small group of refractory patients, even though
some response can be obtained by changing the
therapeutic regimen, survival is very poor (Boccacio
et al., 1983). As HD is highly chemosensitive,
several teams have examined the role of high-dose
combined modality therapy for these patients, with
the support of autologous bone marrow trans-
plantation (ABMT). However, reported results have
been rather rare, due to the small number of cases,
and are usually part of larger series which include
a variety of solid tumours or haematological malig-
nancies (Jagannath et al., 1984; Phillips, 1983a,b;
Spitzer et al., 1983; Schmeizer, 1983).
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In order to have a clearer idea of the results of
ABMT in HD, an inquiry was made among French
teams, by the French Autologous Bone Marrow
Grafting Group. Results of this study are reported
herein and include 17 cases treated in 9 different
centres.
Materials and methods
Patients
Clinical data and prior therapy are summarized in
Table I. One case has been previously reported
(Gorin et al., 1981). Ages were between 10 and 45
(median 22). Stages at diagnosis included IA (1),
IIA (2), IIB (2), IIIA (2), IIIB (1), and IVB (9).
Among the IVB patients, 2 had initial bone marrow
involvement and 8 had lung involvement.
Eleven patients were considered to have
refractory disease and had never achieved complete
remission despite combination chemotherapy and
radiotherapy (see details in Table I). The other six
had relapsed from CR (1st to the 6th relapses), 2
off therapy and 4 on therapy, and presented at time
of ABMT with disease still responsive to rescue
protocols (cases 3, 5 and 17) or not responsive to
rescue protocols (cases 4, 6 and 7). Patients had
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Table I Patients treated by high dose chemotherapy and autologous bone marrow transplantation
Response to the last
Stage at First line Treatment at relapse salvage therapy
Case Age/Sex diagnosis treatment Response (salvage therapy) prior to ABMT
1 17/M IV B BM MOPPx6 PR ABVD x 6 PD
2 36/M IV B Lung MOPPx6 PR ABVDx6 PD
3 22/F III A MOPPx6+RT CR MOPP x 6, ABVD x 3 PR
4 21/M IV B Lung MOPPx6+RT CR CVPP CCNU, ABVD x 8 PD
5 15/M III A MOPPx6+RT CR ABVDx4 PR
6 24/M II A MOPPx3+RT CR MOPPx3, ABVDx3 PD
7 27/M IV B Lung MOPPx4 CR ABVDx3,MOPPx3 PD
ABVD x 4+RT
8 22/M IV B Lung MOPPx6 PR RT PD
9 27/M IV B Lung MOPPx6 PR CVPP x 10, Eldesine, +RT PD
10 34/F II A MOPP x 9 PR ABVD x 2, Eldesine, +RT PD
11 12/F IV B Lung MOPP x4 PR ABVD x 4 PD
12 16/M IIE B MOPP x 3 PR ABVDx3+RT PD
13 31/M IV B Lung, BM MOPPx6 PR ABVDx6 PD
14 33/M IV B Lung MOPP x 6 PR ABVD x 6 PD
15 45/M II B MOPPx4 NR ABVDx4+RT NR
16 35/M III B MOPPx4 PR ABVDx2 PD
17 13/M I A MOPPx4+RT CR ABVDx6 CR
CR complete remission; PR=partial response; NR=no response; RT=radiotherapy.
been treated for a median period of 24 months
prior to ABMT.
At the time of grafting, stages were 11 (3), III (2)
and IV (12) (Table I). All patients except three
(Table I) were progressing at time of ABMT.
Bone marrowfreezing and storage
All patients had uninvolved bone marrow at the
time of harvesting and in vitro purging was not
attempted. The harvest was done under general
anaesthesia and in all cases bone marrow was
cryopreserved according to the usual procedure
(Gorin et al., 1983, Herve et al., 1981). The number
of nucleated cells collected for each case is
described in Table II. For some patients, 2 harvests
were necessary, due to prolonged previous therapy.
High dose therapy and autologous engraftment
Several types of combined modality therapy were
used, the details of which are summarized in
Table III. Each patient except one received
cyclophosphamide and apart from 2, all received
either CCNU or BCNU. Nine patients received the
TACC or BACT combinations, as often used in
non-Hodgkin's lymphomas, and one of these also
received TBI (12Gy). The 8 other patients were
given various regimens, as detailed in Table III.
Three of these 8 were given TBI (1OGy). Bone
marrow was reinfused 48h after the last dose of
cyclophosphamide, 12h after TBI and 72h after
BCNU or CCNU. Patients received a median of
1.2 x108 nucleated cellskg-1 and were nursed in
single rooms until haematologic reconstitution.
Post-treatment evaluation
Patients were evaluated at day 30 and thereafter on
a monthly basis. They were considered to have had
a complete remission only if clinical, radiology and
laboratory tests, including the sedimentation rate,
became normal. Patients who died less than 30 days
after the first day of treatment were not considered
evaluable for tumour response unless there was
clear evidence of progressive disease or autopsy
evidence of remission. No patient received main-
tenance chemotherapy after ABMT.
Results
Anti-tumour effect (Table IV)
Four patients were not evaluable (death on day 4,HIGH DOSE CHEMOTHERAPY AND BMT IN HODGKIN'S DISEASE 739
Table II Number of nucleated cells reinfused, time to hematologic revocery, and other toxicity
<1000 WBCmm-3 <50000 p1mm-3
Case no. x1O8kg (days) (days) Other toxicities
1 1.5 32 28 Haemolytic uraemic syndrome
2 1.2 NE (>6) NE (>6) Cardiomyopathy'
3 1.3 18 16 Herpes simplex
4 1 NE (>15) NE (>15) Cardiomyopathy; renal failurea
5 1.7 12 12 Herpes simplex
6 0.5 11 NE (>20) Septicemia, gastric ulcer, CNS complicationsa
7 0.9 17 22 Septicemia, lung fibrosisa
8 1.9 17 19 Vomiting
9 1 19 20 Septicemia, herpes, cardiomyopathy
10 1 18 8 Herpes, encephalitis
11 2 NE (>21) NE (>21) Septicemiaa
12 1.2 39 13 Pneumocystis
13 1.5 25 30 Late pulmonary disease (CMV) after recovery'
14 0.5 NE (>4) NE (>4) Septicemiaa
15 1.5 20 NE (>35) (Aspergillosis)a
16 0.02 NE (>21) NE (>21) Renal failurea
17 1.5 NE (> 17) NE (> 17) (Aspergillosis)a
aFatal.
Table Ill Summary of protocols
TACC BACT VACC CAC COAC COMAC COCM CCP VPJ6-C VPJ6-A-M
Cyclophosphamide * 0 0 * * 0 * * 0
Aracytin * 0 *
CCNU 0 * * * 0 O
BCNU
6-Thioguanine * a
Vindesine * O
Vincristine 0 0
Adriamycin * * a
Caryolysine a
Melphalan 0
Procarbazide a
Etoposide 0 0
Cyclophosphamide 40-S0mgkg-'; aracytin 200-400mgm-2; B or CCNU 200-400mgm-2; 6 thioguanine 200-
400mgm-2; vindesine 2.5mgm-2; vincristine 2mgm-2; adriamycin 60-100mgm-2; caryolysine 6mgm-2; melphalan
100-140mgm-2; procarbazine 200mgm-2; etoposide 100-6mgm-g2.
6, 17 and 20); 3 of these, however, showed a partial
clinical remission before death. Four patients failed
to respond and died within the first month with
progressive disease. Nine achieved CR, although 2
of these died from treatment related toxicity (cases
4 and 13), but CR was confirmed at autopsy. Four
out of the 8 survivors subsequently relapsed at 3, 4
and 5 months and died within 12 to 17 months.
Nevertheless, 3 long-term survivors are presently
free of disease, and off therapy for more than 25,
43 and 66 months, respectively.
Toxicity (Table II)
Haematopoietic reconstitution is detailed in
Table II.
Seven patients had culture proven sepsis either
during the period of aplasia (5) or within the
following 3 months (2). Organisms isolated included
2 pseudomonas, 2 escherichia coli, 2 aspergillosis,
and 1 cytomegalovirus and were lethal in 6
patients. In 1 case, an acute cardio-respiratory
failure developed possibly due to the toxicity of a740 T. PHILIP et al.
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o < = = v = = g g g g == = = = = v aAGOGLUTINATION OF PERIPHERAL BLOOD LYMPHOCYTES
Histone agglutination test in microtubes. Five min reaction. x 4.
second series the test was done in microtubes
(41 x 8 mm) and evaluated macroscopically.
Both techniques gave the same results.
Test in "microtest plates '.-Lympho-
cytes were washed with Hanks' medium, and
diluted with Hanks' medium at concentra-
tions of 3000 lymphocytes/mm3. Histone
fractions (gift of Dr Johns, Chester Beatty
Institute) were dissolved in 0-145 mol/l
NaCl. Serial dilutions of histone (starting
with 10 jtg in 25 ,ul in the first well) were
then mixed with equal volumes of lympho-
cytes (i.e. 75,000 lymphocytes in 25 ul
per well). The plates were incubated for
30 min at 37°C and examined under the
microscope.
Test in microtubes.-Lymphocytes were
washed again with PBS and suspended in
PBS at a concentration of 3000 lympho-
cytes/mm3. 0-25 ml of this suspension was
distributed in microtubes (41 x 8 mm) and
20 ,tg of histone fraction was added to the
test tube. The reaction was read after
5 min and verified again after 30 min,
without incubation at 37°C. Where there
was a positive reaction the agglutination
of lymphocytes was clearly visible (see
Figure).
For electrophoretic mobility analysis,
the incubation at room temperature was
stopped after 5 min and cells were washed
with 0-145 mol/l NaCI, pH 7-2, and measured
in cylindrical electrophoresis apparatus as
described (Sabolovic et al., 1974).
RESULTS
Patients with various tumours were
tested, together with patients with a
variety of other diseases. They included
patients without treatment as well as
those under treatment. Moreover, some
ofthe patients were followed up for a 5-10
month period and retested at irregular
intervals. The controls included normal
subjects ofboth sexes and all ages, normal
thymus cells and tonsil lymphocytes.
Table I shows the results obtained
with all patients tested and Table II
shows the evolution of sensitivity to
agglutination in 3 individual patients.
All 5 fractions of histones (Fl, F2A1,
F2A2, F2B and F3) were tested but
positive reactions were observed only
with F2A1 and sometimes with F2A1,
F2B and F3 (Table I). 76% of all
patients were positive in our test com-
pared with negative reactions in 59
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